Altamira Therapeutics Ltd (FRA:2QA)
€ 948 0 (0%) Market Cap: 2.67 Mil Enterprise Value: 2.14 Mil PE Ratio: 0 PB Ratio: 0.26 GF Score: 36/100

Q4 2022 Altamira Therapeutics Ltd Earnings Call Transcript

May 16, 2023 / 12:00PM GMT
Release Date Price: €948
Operator

Good morning, and welcome to the Altamira Therapeutics 2022 Results Conference Call. On today's call are Thomas Meyer, Altamira's Founder, Chairman and Chief Executive Officer; and Covadonga Pañeda, Altamira's Chief Operating Officer.

Earlier today, Altamira issued a news release with the full year 2022 financial results as well as a comprehensive business update. The release is available on the company's website at www.altamiratherapeutics.com and has been filed with the SEC. During today's call, the company will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements that address future operating, financial or business performance or its strategies or expectations. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot